Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Absci Corp(ABSI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABSI
11/13/2026: ABSI (4-star) is currently NOT-A-BUY. Pass it for now.
Absci Corp is a biotechnology firm that leverages generative artificial intelligence to design and develop novel protein-based therapeutics. The company's primary strength lies in its integrated, end-to-end platform that combines machine learning with laboratory validation. Its main investment narrative centers on potentially reducing drug development timelines and costs through AI, which has attracted partnerships with large pharmaceutical companies. However, the firm faces risks related to clinical success, intense competition in the AI drug discovery space, and the high-burn nature of its pre-profit business model. This stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to the long-term convergence of AI and drug development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Absci represents a high-risk, high-reward play on the integration of AI into pharmaceutical discovery. |
| Momentum investor | Mixed fit | Momentum depends on positive clinical updates or partnership announcements which can be infrequent and volatile. |
| Value investor | Weak fit | As a pre-profit, R&D-focused company, Absci does not fit traditional value metrics. |
| Dividend investor | Weak fit | The company is in a growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | The inherent risks of biotechnology and AI-driven business models lead to high price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences significant price swings due to its early-stage status and reliance on news-driven events. |
| Valuation risk | High | Valuations for pre-profit biotech firms are often subjective and based on long-term, uncertain pipeline potential. |
| Competition risk (AI competition) | Medium / high | The AI drug discovery space is crowded with well-funded competitors. |
| Business quality | Medium | While the technology platform is specialized, the business is still unproven at scale in terms of recurring profitability. |
| Dividend income | Low / none | Income investors should not look to this stock for yield. |
| Execution risk | Medium / high | Success requires the precise integration of AI design with laboratory experimental validation. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.57B USD | Price to earnings Ratio - | 1Y Target Price 14.82 |
Price to earnings Ratio - | 1Y Target Price 14.82 | ||
Volume (30-day avg) 4.2M shares | Beta 2.19 | 52 Weeks Range 2.24 - 12.54 | Updated Date 11/13/2026 |
52 Weeks Range 2.24 - 12.54 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 113.74% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Partnership Revenue | Upfront payments, research milestone payments, and future potential royalties from drug programs. | Revenue is not from a mass-market product but from individual, contract-based collaboration deals with other drug companies. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.53B | Price to Sales(TTM) 1054.27 |
Enterprise Value 1.53B | Price to Sales(TTM) 1054.27 | ||
Enterprise Value to Revenue 981.78 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 171.61M | Shares Floating 164.69M |
Shares Outstanding 171.61M | Shares Floating 164.69M | ||
Percent Insiders 11.78 | Percent Institutions 88.81 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.